Anzeige
❌
Mehr »
Freitag, 20.11.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Pharmaceutical Technology

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
12:46Novartis CEO leans on surge of pipeline readouts to quell growth fears
12:46Sanofi rumoured to be eyeing high-profile Insmed takeover
DoRecursion CEO details novel Phase III endpoint for rare disease drug
DoGeopolitical pressures and greater buyer selectivity hamper M&A deal closure rates
DoEllipses Pharma plots London listing that could end British biotech IPO drought
DoAbbVie and Disco ink $2.5bn pact for next-generation cancer bispecifics
DoPfizer inks $2.6bn autoimmune deal with China's Starna for CAR-T therapies
DoBridging gaps in rare disease drug access requires strategic rethink
DoGenomics, Vertex extend drug discovery alliance in $220m deal
DoFDA approves Regeneron's Livsayis for generalised myasthenia gravis
MiEuropean capital markets require efforts to attract biotech listings
MiGSK's $10.6bn Nuvalent bet pays off with second lung cancer drug approval
MiIsomorphic Labs raises $5bn to advance drug pipeline
MiRevolution Medicines' Rasonque gains EC authorisation for pancreatic cancer
DiEli Lilly inks cancer pact worth up to $5.9bn with Stipple Bio
DiPfizer CEO: 'China will be my major competition by 2030'
DiSeawolf Therapeutics and Sanofi agree $1.2bn drug deal
DiUK biotech sector calls on government to support sector's growth on home soil
DiLilly agrees to acquire Calytrix Bio for $1.5bn
MoJ&J outlays up to $3.3bn to buy ophthalmology specialist Ollin Biosciences
MoRevMed CEO on tackling "complex" launch for wonder pancreatic drug
MoFlagship Pioneering expands to UK with £100m AI-native lab
MoSofinnova Partners backs European life sciences sector with €725M raise
MoAstraZeneca secures FDA approval for Imfinzi combo in MIBC
MoFDA rejects Summit's ivonescimab application for lung cancer